Market Human Health
An Overview of the Global Cancer Market
Cancer is a serious and widespread disease affecting millions of people around the world.
According to the World Health Organization (WHO), in 2012, about 8.2 million people died of cancer and an increasing number of new cases of affected people each year. In 2030, 13.1 million people are expected to die from the disease. In particular, increased life expectancy worldwide has contributed the most to the increase in cancer rates. The market for cancer drugs is the largest segment in the pharmaceutical industry in terms of value and exceeds $100 billion. It is expected to amount to almost $150 billion in 2018. Cytostatics comprise around 40% of the market for cancer drugs. Despite the development and introduction of new drugs for the treatment of cancer, cytostatics are still, in combination with other treatments such as surgery and radiation treatment, the primary form of treatment for cancer worldwide. Cytostatics usually work by preventing the division of cells. The reproduction of cancer cells is thus inhibited and the growth of tumors is suppressed. Many new drugs for the treatment of cancer which have been approved for sale are used together with one or more cytostatics. Furthermore, many drug candidates under development are not water-soluble and require innovative formulations to be able to be used intravenously.
The main competitor for Oasmia’s product Apealea (Paclical) is Abraxane, a product which is marketed by Celgene. Abraxane contains human albumin bound to paclitaxel and generated revenues of MUSD 967.5 in 2015. The active substance in Docecal is docetaxel, whose patent started to expire in 2010. At present competition comes from several generic preparations together with the original product Taxotere. Before the patent expired, the product experienced sales of just under $3 billion in 2009.
Cancer of the ovaries or fallopian tubes is a serious disease that often leads to death if it is detected too late and metastases have formed. As the symptoms for ovarian cancer are vague, the disease difficult to diagnose and often discovered too late. Each year, Sweden has reported just over 700 cases. The global market for ovarian cancer treatment was $ 551 million in 2010, and it has an expected annual growth rate of 13.6% until 2017. The largest regional market in terms of capital is the United States of America (USA), which is expected to have just over 22,200 cases in 2016.
Breast cancer is one of the most common cancers. According to WHO, 1.38 million women are diagnosed with breast cancer each year. Roughly 458,000 women worldwide die from the disease annually. In Sweden, 7,950 women were affected in 2010. The total market for the treatment of breast cancer during the same year amounted to $ 9.8 billion, with a projected annual growth rate of 3.4% until 2017.